Form 8-K - Current report:
SEC Accession No. 0001493152-25-006126
Filing Date
2025-02-12
Accepted
2025-02-12 16:10:57
Documents
17
Period of Report
2025-02-06
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 50876
2 ex4-1.htm EX-4.1 96544
3 ex4-2.htm EX-4.2 61556
4 ex10-1.htm EX-10.1 76961
5 ex10-2.htm EX-10.2 79486
  Complete submission text file 0001493152-25-006126.txt   608677

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE ppcb-20250206.xsd EX-101.SCH 3012
7 XBRL LABEL FILE ppcb-20250206_lab.xml EX-101.LAB 34240
8 XBRL PRESENTATION FILE ppcb-20250206_pre.xml EX-101.PRE 22357
20 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3447
Mailing Address 302/6 BUTLER STREET CAMBERWELL, VICTORIA C3 3124
Business Address 302/6 BUTLER STREET CAMBERWELL, VICTORIA C3 3124 61-03-9882-0780
Propanc Biopharma, Inc. (Filer) CIK: 0001517681 (see all company filings)

EIN.: 330662986 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 000-54878 | Film No.: 25614904
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)